Explore

Rapid ReadRapid Read
Advanced Genetic Testing Expands Treatment Options for Cancer Patients, Study Finds

Advanced Genetic Testing Expands Treatment Options for Cancer Patients, Study Finds

A study conducted by researchers at Western University's Schulich School of Medicine & Dentistry and London Health Sciences Centre Research Institute (LHSCRI) has revealed that advanced genetic testing can significantly broaden treatment options for cancer patients. The prospective study, named Precision Oncology at Western University (POWER) and published in The Journal of Molecular Diagnostics, utilized next-generation sequencing to analyze hundreds of cancer-related genes simultaneously. This approach uncovered genetic changes that standard-of-care testing often misses. The findings indicate that nearly one in three patients became eligible for therapies not typically used for their specific cancer type, based on the unique DNA of their tumor. This expanded testing also provided access to clinical trials, off-label therapies, and compassionate access programs that were previously unavailable to these patients.
Rapid ReadRapid Read
Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision Oncology Shifts Towards Integrating Multiple Biomarkers for Treatment Decisions

Precision oncology is increasingly moving beyond the reliance on single biomarkers to guide treatment decisions, instead emphasizing the integration of multiple genomic and molecular tests. Experts in a roundtable discussion highlighted that understanding cancer now requires combining diverse sources of molecular information to better comprehend tumor biology and personalize patient care. For instance, in colorectal cancer, the presence of both BRAF V600E mutation and MSI-high status provides two actionable biomarkers, often leading to immunotherapy as the initial treatment. In breast oncology, gene expression assays like Oncotype DX, which evaluate 21 genes, have been used for decades to determine which patients with early-stage ER-positive, HER2-negative breast cancer would benefit from chemotherapy, sparing millions from unnecessary treatments. The discussion also touched upon the complementary roles of protein-based and genomic testing for markers like microsatellite instability and HER2 status, indica...
Rapid ReadRapid Read
La Vie Health and Virotek Biosciences Partner to Integrate Genomic Insights into Preventive Health

La Vie Health and Virotek Biosciences Partner to Integrate Genomic Insights into Preventive Health

La Vie Health, a Canadian physician-led preventive and precision health organization, has announced a strategic collaboration with Virotek Biosciences. This partnership aims to integrate advanced genomic insights into La Vie's existing physician-led preventative, precision, and healthspan model. Virotek Biosciences will contribute a clinically contextualized genomic layer to La Vie's comprehensive precision-health programs. The collaboration is rooted in La Vie's 'Predict-to-Prevent' philosophy, which focuses on optimizing long-term healthspan by integrating multiple layers of health information. This includes genomics, biomarkers, imaging, cardiovascular and metabolic health, body composition, fitness and physiology, lifestyle, and medical and family history. La Vie physicians will interpret these findings to develop personalized preventive strategies and provide long-term patient follow-up. Virotek's platform integrates genetic results with demographic and clinical factors to provide actionable insights,...
Rapid ReadRapid Read
Bionano Genomics Studies Reveal Optical Genome Mapping's Clinical Value in High-Risk Hematologic Malignancies

Bionano Genomics Studies Reveal Optical Genome Mapping's Clinical Value in High-Risk Hematologic Malignancies

Bionano Genomics, Inc. has highlighted three new peer-reviewed studies demonstrating the clinical utility of its optical genome mapping (OGM) technology in high-risk hematologic malignancies. These studies, conducted by independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute, focused on myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms (t-MN). The research indicates that OGM can detect prognostically important structural genomic alterations that are often missed by conventional methods such as standard karyotyping, FISH, and targeted sequencing panels. For instance, the MD Anderson study found that OGM identified chromoanagenesis in a significant percentage of MDS cases, correlating with a much shorter median overall survival. The University of Oulu study revealed clinically relevant structural variants in nearly half of cytogenetically normal AML cases, which were associated with...
Rapid ReadRapid Read
Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.
Rapid ReadRapid Read
New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

New Research Identifies Integrated Biomarkers for Rectal Cancer Treatment Response

A recent study published in Frontiers in Genetics has identified integrated biomarkers that link systemic inflammation and nutrition status to the tumor immune microenvironment, providing insights into neoadjuvant response in locally advanced rectal cancer (LARC). The research focused on the inflammation-nutrition prognostic score (INPS), calculated as the neutrophil-to-lymphocyte ratio (NLR) divided by the prognostic nutritional index (PNI). This score integrates systemic inflammatory burden and nutritional-immunological reserve. The study retrospectively analyzed 312 LARC patients who received standard neoadjuvant chemoradiotherapy, with or without concurrent PD-1/PD-L1 blockade, followed by total mesorectal excision. The findings indicate that a low INPS (<0.058) was significantly associated with a higher objective response rate (61.3% vs. 29.4%) and pathological complete response (38.7% vs. 11.8%). The INPS demonstrated a strong predictive capability for treatment response, outperforming other individu...
TrendlineTrendline
Biotechnology ETFs Offer Investment Opportunities in U.S. Market

Biotechnology ETFs Offer Investment Opportunities in U.S. Market

Biotechnology ETFs Offer Investment Opportunities in U.S. Market
Rapid ReadRapid Read
Evvy Secures $40 Million Series B to Advance Women's Health Research with Vaginal Microbiome Data

Evvy Secures $40 Million Series B to Advance Women's Health Research with Vaginal Microbiome Data

Evvy, a women's health company, announced it has raised $40 million in a Series B funding round led by Catalio Capital Management. Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy is recognized for its at-home CLIA-certified and CLEP-certified mNGS test, which analyzes vaginal microbes using a single swab. Users send their samples to Evvy's lab for mNGS sequencing, with results reviewed by clinicians on its platform and then posted to the patient's health portal. The company states it has served over 100,000 patients across the United States and collaborates with 3,000 practitioners. Evvy has also contributed to 15 peer-reviewed publications and abstracts, identifying novel BV subtypes and hundreds of previously uncatalogued vaginal microbiome genomes. Clinicians utilizing Evvy's platform can leverage this data for personalized patient treatments. Beyond direct patient care, Evvy aims to build a comprehensive dataset linking microbiome biology, symptoms, interventions, and health out...
Rapid ReadRapid Read
BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene Expands AI-Powered Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research

BostonGene, a developer of AI models for tumor and immune biology, has expanded its scientific collaboration with the Dana-Farber Cancer Institute. This expanded partnership aims to deepen the understanding of the complex biological mechanisms driving BRCA1- and BRCA2-associated breast cancers. The collaboration will utilize BostonGene's foundation model of tumor and immune biology and multimodal AI analytics to place individual tumors within a broader biological context. This approach seeks to systematically discover mechanisms that differentiate disease subtypes, drive therapeutic response, and contribute to resistance. The research will focus on BRCA1/2-associated ER-positive breast cancer (BRCA ER+), TP53-mutant ER-positive breast cancer (TP53 ER+), and triple-negative breast cancer (TNBC).
Rapid ReadRapid Read
AI Tools Enhance Immunotherapy Outcome Prediction in Lung Cancer Patients

AI Tools Enhance Immunotherapy Outcome Prediction in Lung Cancer Patients

Artificial intelligence (AI) tools are demonstrating significant potential in predicting treatment and survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy. A new study, published in Nature Medicine and stemming from the I3LUNG project, highlights the development of AI-based predictive models designed to optimize therapeutic approaches for individual patients. Immunotherapy, while transformative for 20% to 30% of lung cancer patients, often faces resistance, and current prediction methods, largely based on PD-L1 expression, have limitations. The I3LUNG project integrated diverse patient data, including clinical, imaging, pathology, and genomic information, to train and validate two families of AI models. These models consistently outperformed standard clinical biomarkers, with one model achieving an AUC score of 0.88 when incorporating clinical, blood, imaging, and digital pathology data. The study also found that AI support improved physicians' ability t...
TrendlineTrendline
North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment

North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment

North Texas Emerges as a Hub for Longevity Industry, Attracting Billions in Investment
Rapid ReadRapid Read
Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare

Tempus AI, Inc. (NASDAQ: TEM) has announced a new initiative to create a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This effort aims to establish the first de-identified multimodal whole-genome sequencing (WGS) dataset specifically optimized for AI-driven research, built around disease populations and patient outcomes. Following the completion of this initial dataset, Tempus plans to expand the project with a long-term goal of reaching one million genomes. Unlike existing population-scale genome programs that primarily draw from general populations, Tempus's dataset will integrate genomic data with longitudinal disease and treatment outcomes. The company has already developed one of the largest multimodal real-world oncology databases, which has been used to inform drug development decisions. This new WGS dataset will be incorporated into Tempus’ existing de-identified multimodal data environment, allowing researchers to acces...